PDCD1 and neoplasm: Emerging studies have reported that NPC tumor cells highly express PD-L1, with a positive expression rate from 89% to 100% (28), however, only 20%-30% of NPC patients respond well to anti-PD-L1/PD-1 therapy (8–10).